Cancer-Associated Thrombosis: Beyond Clinical Practice Guidelines-A Multidisciplinary (SEMI-SEOM-SETH) Expert Consensus

Vanessa Pachón, Javier Trujillo-Santos, Pere Domènech, Enrique Gallardo, Carmen Font, José Ramón González-Porras, Pedro Pérez-Segura, Ana Maestre, José Mateo, Andrés Muñoz, María Luisa Peris, Ramón Lecumberri, Vanessa Pachón, Javier Trujillo-Santos, Pere Domènech, Enrique Gallardo, Carmen Font, José Ramón González-Porras, Pedro Pérez-Segura, Ana Maestre, José Mateo, Andrés Muñoz, María Luisa Peris, Ramón Lecumberri

Abstract

Despite the growing interest and improved knowledge about venous thromboembolism in cancer patients in the last years, there are still many unsolved issues. Due to the limitations of the available literature, evidence-based clinical practice guidelines are not able to give solid recommendations for challenging scenarios often present in the setting of cancer-associated thrombosis (CAT). A multidisciplinary expert panel from three scientific societies-Spanish Society of Internal Medicine (SEMI), Spanish Society of Medical Oncology (SEOM), and Spanish Society Thrombosis and Haemostasis (SETH)-agreed on 12 controversial questions regarding prevention and management of CAT, which were thoroughly reviewed to provide further guidance. The suggestions presented herein may facilitate clinical decisions in specific complex circumstances, until these can be made leaning on reliable scientific evidence.

Keywords: cancer; prophylaxis; pulmonary embolism; treatment; venous thrombosis.

Conflict of interest statement

Conflicts of Interest V.P. Advisory board: Daiichi-Sankyo.

E.G. Speaker honoraria: Rovi and Leo Pharma; advisory board: Sanofi, Leo Pharma, and Daiichi-Sankyo.

A.M. Speaker honoraria: Rovi; advisory board: Sanofi, Leo Pharma, and Daiichi-Sankyo.

R.L. Speaker honoraria: Rovi and Boehringer-Ingelheim; advisory board: Sanofi, Leo Pharma, and BMS. Research grant: Rovi.

All other authors declare no relevant conflict of interest associated with this work.

References

    1. Lyman G H, Khorana A A, Kuderer N M et al.Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(17):2189–2204.
    1. Guyatt G H, Akl E A, Crowther M, Gutterman D D, Schuünemann H J; American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel.Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 2012141(2, Suppl):7S–47S.
    1. Mandalà M, Falanga A, Roila F; ESMO Guidelines Working Group.Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines Ann Oncol 20112206vi85–vi92.
    1. Farge D, Debourdeau P, Beckers M et al.International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost. 2013;11(01):56–70.
    1. Muñoz A J, Viñolas N, Cubedo R, Isla D. SEOM guidelines on thrombosis in cancer patients. Clin Transl Oncol. 2011;13(08):592–596.
    1. Jimenez-Fonseca P, Carmona-Bayonas A, Calderon C et al.FOTROCAN Delphi consensus statement regarding the prevention and treatment of cancer-associated thrombosis in areas of uncertainty and low quality of evidence. Clin Transl Oncol. 2017;19(08):997–1009.
    1. Khorana A A, Kuderer N M, Culakova E, Lyman G H, Francis C W. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902–4907.
    1. Mansfield A S, Tafur A J, Wang C E, Kourelis T V, Wysokinska E M, Yang P. Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer. J Thromb Haemost. 2016;14(09):1773–1778.
    1. Chaudhury A, Balakrishnan A, Thai C et al.Validation of the Khorana score in a large cohort of cancer patients with venous thromboembolism. Blood. 2016;128:879.
    1. Srikanthan A, Tran B, Beausoleil M et al.Large retroperitoneal lymphadenopathy as a predictor of venous thromboembolism in patients with disseminated germ cell tumors treated with chemotherapy. J Clin Oncol. 2015;33(06):582–587.
    1. Muñoz Martín A J, Ortega I, Font C et al.Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer. Br J Cancer. 2018;118(08):1056–1061.
    1. Van Es N, Di Nisio M, Cesarman G et al.Comparison of risk prediction scores for cancer-associated venous thromboembolism: a prospective cohort study. Haematologica. 2017;102(09):1494–1501.
    1. Gerotziafas G T, Taher A, Abdel-Razeq H et al.A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS-Cancer-Associated Thrombosis Study. Oncologist. 2017;22(10):1222–1231.
    1. Cella C A, Di Minno G, Carlomagno C et al.Preventing venous thromboembolism in ambulatory cancer patients: the ONKOTEV Study. Oncologist. 2017;22(05):601–608.
    1. Pabinger I, van Es N, Heinze G et al.A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. Lancet Haematol. 2018;5(07):e289–e298.
    1. Soria J M, López S. [The genetics of thrombosis in cancer] Med Clin (Barc) 2015;144 01:26–30.
    1. Antic D, Biljana M, Milic Net al.Internal and external validation of THROLY (thrombosis lymphoma) score Thromb Res 2018164(suppl 1):S187
    1. Norris L A, Abu Saadeh F, Ward Met al.Development and validation of a risk model for prediction of venous thromboembolism in gynaecological cancer patients Thromb Res 2018164(suppl 1):S183–S184.
    1. Harenberg J, Roebruck P, Heene D L; The Heparin Study in Internal Medicine Group.Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients Haemostasis 19962603127–139.
    1. Lechler E, Schramm W, Flosbach C W; The Prime Study Group.The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin) Haemostasis 1996260249–56.
    1. Samama M M, Cohen A T, Darmon J Y et al.A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med. 1999;341(11):793–800.
    1. Leizorovicz A, Cohen A T, Turpie A G, Olsson C G, Vaitkus P T, Goldhaber S Z; PREVENT Medical Thromboprophylaxis Study Group.Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients Circulation 200411007874–879.
    1. Cohen A T, Davidson B L, Gallus A Set al.Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial BMJ 2006332(7537):325–329.
    1. Carrier M, Khorana A A, Moretto P, Le Gal G, Karp R, Zwicker J I. Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer. Am J Med. 2014;127(01):82–60.
    1. Giantonio B J, Catalano P J, Meropol N J et al.Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25(12):1539–1544.
    1. Hurwitz H, Fehrenbacher L, Novotny W et al.Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–2342.
    1. Van Cutsem E, Rivera F, Berry S et al.Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol. 2009;20(11):1842–1847.
    1. Flynn P J, Sugrue M M, Purdie D Met al.Serious bleeding events are uncommon in patients with metastatic colorectal cancer receiving bevacizumab as part of a first-line regimen: results from the BRiTE Observational Cohort Study J Clin Oncol 200826(Suppl 15):4104
    1. Griesinger F, Laskin J J, Pavlakis N.Safety of first-line bevacizumab-based therapy with concomitant cardiovascular or anticoagulation medication in advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) in MO19390 (SAiL) J Clin Oncol 200826(Suppl 15):8049
    1. Hambleton J, Novotny W F, Hurwitz Het al.Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation J Clin Oncol 200422(Suppl 14):3528
    1. Wardley A, Lohrisch C, Joy A A et al.Effect of anticoagulation therapy on bleeding and thromboembolic events (TEs) in the AVADO phase III study of docetaxel (D) ± bevacizumab (BV) in inoperable locally recurrent (LR) or metastatic breast cancer (mBC) Cancer Res. 2009;69 02:1035.
    1. Leighl N B, Bennouna J, Yi J, Moore N, Hambleton J, Hurwitz H. Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study. Br J Cancer. 2011;104(03):413–418.
    1. Hurwitz H I, Saltz L B, Van Cutsem E et al.Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol. 2011;29(13):1757–1764.
    1. Abdel-Razeq H, Mansour A, Ismael Y, Abdulelah H. Inferior vena cava filters in cancer patients: to filter or not to filter. Ther Clin Risk Manag. 2011;7:99–102.
    1. Mansour A, Ismael Y, Abdel-Razeq H. Inferior vena cava filters in patients with advanced-stage cancer. Hematol Oncol Stem Cell Ther. 2014;7(04):136–141.
    1. Barginear M F, Gralla R J, Bradley T P et al.Investigating the benefit of adding a vena cava filter to anticoagulation with fondaparinux sodium in patients with cancer and venous thromboembolism in a prospective randomized clinical trial. Support Care Cancer. 2012;20(11):2865–2872.
    1. Mikhail S, Hannan L, Pishvaian M J, Kessler C. Retrievable inferior vena cava filters in patients with cancer are safe but are they beneficial? Med Oncol. 2015;32(06):622.
    1. Abtahian F, Hawkins B M, Ryan D P et al.Inferior vena cava filter usage, complications, and retrieval rate in cancer patients. Am J Med. 2014;127(11):1111–1117.
    1. Brunson A, Ho G, White R, Wun T. Inferior vena cava filters in patients with cancer and venous thromboembolism (VTE) does not improve clinical outcomes: a population-based study. Thromb Res. 2017;153:57–64.
    1. Coombs C, Kuk D, Devlin S et al.Outcomes after inferior vena cava filter placement in cancer patients diagnosed with pulmonary embolism: risk for recurrent venous thromboembolism. J Thromb Thrombolysis. 2017;44(04):489–493.
    1. Carrier M, Khorana A A, Zwicker J, Noble S, Lee A Y; Subcommittee on Haemostasis and Malignancy for the SSC of the ISTH.Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH J Thromb Haemost 201311091760–1765.
    1. Lyman G H, Bohlke K, Khorana A A et al.Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline update 2014. J Clin Oncol. 2015;33(06):654–656.
    1. Kearon C, Akl E A, Ornelas J et al.Antithrombotic therapy for VTE disease. Chest guideline and expert panel report. Chest. 2016;149(02):315–352.
    1. Farge D, Bounameaux H, Brenner B et al.International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2016;17(10):e452–e466.
    1. Duffett L, Carrier M. Inferior vena cava filters. J Thromb Haemost. 2017;15(01):3–12.
    1. Pandhi M B, Desai K R, Ryu R K, Lewandowski R J. The role of inferior vena cava filters in cancer patients. Semin Intervent Radiol. 2016;33(02):71–74.
    1. American Society of Hematology.Ten things physicians and patients should questionAvailable at:. Accessed October 15, 2018
    1. Lee A Y, Peterson E A. Treatment of cancer-associated thrombosis. Blood. 2013;122(14):2310–2317.
    1. Elalamy I, Mahé I, Ageno W, Meyer G. Long-term treatment of cancer-associated thrombosis: the choice of the optimal anticoagulant. J Thromb Haemost. 2017;15(05):848–857.
    1. Francis C W, Kessler C M, Goldhaber S Z et al.Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. J Thromb Haemost. 2015;13(06):1028–1035.
    1. Jara-Palomares L, Solier-Lopez A, Elias-Hernandez T et al.Tinzaparin in cancer associated thrombosis beyond 6 months: TiCAT study. Thromb Res. 2017;157:90–96.
    1. Noble S, Sui J. The treatment of cancer associated thrombosis: does one size fit all? Who should get LMWH/warfarin/DOACs? Thromb Res. 2016;140 01:S154–S159.
    1. Zwicker J I, Bauer K A. How long is long enough? Extended anticoagulation for the treatment of cancer-associated deep vein thrombosis. J Clin Oncol. 2014;32(32):3596–3599.
    1. Raskob G E, van Es N, Verhamme P et al.Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378(07):615–624.
    1. Lee A Y, Levine M N, Baker R I et al.Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(02):146–153.
    1. Young A M, Marshall A, Thirlwall J et al.Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D) J Clin Oncol. 2018;36(20):2017–2023.
    1. Streiff M B, Holmstrom B, Ashrani A et al.Cancer-associated venous thromboembolic disease, version 1.2015. J Natl Compr Canc Netw. 2015;13(09):1079–1095.
    1. Olmos V P, Ramos Gallo M J, Rebollo M A et al.Manejo de la enfermedad tromboembólica venosa en pacientes oncológicos: guías de práctica clínica española. Consenso SEACV-SEOM. Med Clin (Barc) 2015;144 01:3–15.
    1. Debourdeau P, Farge D, Beckers M et al.International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost. 2013;11(01):71–80.
    1. Baumann Kreuziger L, Cote L, Verhamme P et al.A RIETE registry analysis of recurrent thromboembolism and hemorrhage in patients with catheter-related thrombosis. J Vasc Surg Venous Lymphat Disord. 2015;3(03):243–500.
    1. Delluc A, Le Gal G, Scarvelis D, Carrier M. Outcome of central venous catheter associated upper extremity deep vein thrombosis in cancer patients. Thromb Res. 2015;135(02):298–302.
    1. Levin J M, Schiff D, Loeffler J S, Fine H A, Black P M, Wen P Y. Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology. 1993;43(06):1111–1114.
    1. Donato J, Campigotto F, Uhlmann E J et al.Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study. Blood. 2015;126(04):494–499.
    1. Chai-Adisaksopha C, Linkins L A, ALKindi S Y, Cheah M, Crowther M A, Iorio A. Outcomes of low-molecular-weight heparin treatment for venous thromboembolism in patients with primary and metastatic brain tumours. Thromb Haemost. 2017;117(03):589–594.
    1. Zwicker J I, Karp Leaf R, Carrier M. A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation. J Thromb Haemost. 2016;14(09):1736–1740.
    1. Ageno W, Riva N, Schulman S et al.Long-term clinical outcomes of splanchnic vein thrombosis. Results of an International Registry. JAMA Intern Med. 2015;175(09):1474–1480.
    1. Riva N, Ageno W, Schulman S et al.Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry. Lancet Haematol. 2016;3(06):e267–e275.
    1. Tufano A, Ageno W, Di Micco P et al.Outcomes during anticoagulation in patients with symptomatic vs. incidental splanchnic vein thrombosis. Thromb Res. 2018;164:69–74.
    1. Easaw J C, Shea-Budgell M A, Wu C M et al.Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 2: treatment. Curr Oncol. 2015;22(02):144–155.
    1. Oo T H. Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH: a rebuttal. J Thromb Haemost. 2014;12(01):115–116.
    1. Ibrahim R B, Skewes M D, Kuriakose P. “Sailing in troubled waters”: a review of the use of anticoagulation in adult cancer patients with thrombocytopenia. Blood Coagul Fibrinolysis. 2016;27(06):615–630.
    1. Samuelson Bannow B T, Walter R B, Gernsheimer T B, Garcia D A. Patients treated for acute VTE during periods of treatment-related thrombocytopenia have high rates of recurrent thrombosis and transfusion-related adverse outcomes. J Thromb Thrombolysis. 2017;44(04):442–447.
    1. Mantha S, Miao Y, Wills J, Parameswaran R, Soff G A. Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study. J Thromb Thrombolysis. 2017;43(04):514–518.
    1. Samuelson Bannow B T, Lee A, Khorana A A et al.Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH. J Thromb Haemost. 2018;16(06):1246–1249.
    1. Hutten B A, Prins M H, Gent M, Ginsberg J, Tijssen J G, Büller H R. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol. 2000;18(17):3078–3083.
    1. Hirsh J, Bauer K A, Donati M Bet al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8 th edition) Chest 2008133(6, Suppl):141S–159S.
    1. Macle L, Cairns J, Leblanc K et al.2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Can J Cardiol. 2016;32(10):1170–1185.
    1. You J J, Singer D E, Howard P Aet al.Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 2012141(2, Suppl):e531S–e575S.
    1. Rubboli A, Halperin J L, Airaksinen K E et al.Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. Ann Med. 2008;40(06):428–436.
    1. Kirchhof P, Benussi S, Kotecha D et al.2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–2962.
    1. Martin K. Risk factors for and management of MPN-associated bleeding and thrombosis. Curr Hematol Malig Rep. 2017;12(05):389–396.
    1. Landolfi R, Marchioli R, Kutti J et al.Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350(02):114–124.
    1. De Stefano V, Za T, Rossi E et al.Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica. 2008;93(03):372–380.
    1. Lee A YY, Kamphuisen P W, Meyer G et al.Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA. 2015;314(07):677–686.
    1. Meyer G, Marjanovic Z, Valcke J et al.Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002;162(15):1729–1735.
    1. Kreuziger L B, Streiff M. Anti-Xa monitoring of low-molecular-weight heparin in adult patients with cancer. Hematology (Am Soc Hematol Educ Program) 2016;2016(01):206–207.
    1. Garcia D A, Baglin T P, Weitz J I, Samama M M.Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 2012141(2, Suppl):e24S–e43S.
    1. Muñoz Martín A J, Font Puig C, Navarro Martín L M, Borrega García P, Martín Jiménez M; Spanish Society for Medical Oncology.Clinical guide SEOM on venous thromboembolism in cancer patients Clin Transl Oncol 201416121079–1090.
    1. Lim W. Using low molecular weight heparin in special patient populations. J Thromb Thrombolysis. 2010;29(02):233–240.
    1. Connors J M. Thrombophilia testing and venous thrombosis. N Engl J Med. 2017;377(12):1177–1187.
    1. Kearon C, Akl E A, Comerota A Jet al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9 th ed: American College of Chest Physicians evidence-based clinical practice guidelines Chest 2012141(2, Suppl):e419S–e496S.
    1. Baglin T, Bauer K, Douketis J, Buller H, Srivastava A, Johnson G; SSC of the ISTH.Duration of anticoagulant therapy after a first episode of an unprovoked pulmonary embolus or deep vein thrombosis: guidance from the SSC of the ISTH J Thromb Haemost 20121004698–702.
    1. Howard L S, Hughes R J. NICE guideline: management of venous thromboembolic diseases and role of thrombophilia testing. Thorax. 2013;68(04):391–393.
    1. Horowitz N, Brenner B.Thrombophilia and cancer Pathophysiol Haemost Thromb 200836(3-4):131–136.
    1. Baglin T, Gray E, Greaves M et al.Clinical guidelines for testing for heritable thrombophilia. Br J Haematol. 2010;149(02):209–220.
    1. van Sluis G L, Söhne M, El Kheir D Y, Tanck M W, Gerdes V E, Büller H R. Family history and inherited thrombophilia. J Thromb Haemost. 2006;4(10):2182–2187.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit